---
schema_version: "secwatch.filing_event.v1"
accession: "0001847367-26-000016"
form_type: "8-K"
ticker: "ALMS"
cik: "0001847367"
company_name: "ALUMIS INC."
filed_at: "2026-08-13T20:07:36+00:00"
generated_at: "2026-08-13T20:10:32.030664+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alumis Q2 2026: ONWARD3 shows 54% PASI 100; NDA on track for Q4

## Summary
- ONWARD3: 75% PASI 90, 54% PASI 100 at 48 weeks (n=773) for envudeucitinib in PsO.
- NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis on track for Q4 2026.
- Phase 2b LUMUS topline data in SLE expected Q3 2026; prioritizing Sjögren's and CLE.
- Q2 net loss $142.2M vs net income $59.3M (incl. $187.9M ACELYRIN gain); $41.8M lonigutamab impairment.
- Cash $502.3M; guidance funds into Q4 2027.

## SEC filing metadata
- accession: 0001847367-26-000016
- form_type: 8-K
- ticker: ALMS
- cik: 0001847367
- company_name: ALUMIS INC.
- filed_at: 2026-08-13T20:07:36+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/0001847367-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847367-26-000016
- JSON: https://secwatch.observer/filing/0001847367-26-000016.json
- Plain text: https://secwatch.observer/filing/0001847367-26-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.